Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more
Vicore Pharma Holding AB (publ) - Asset Resilience Ratio
Vicore Pharma Holding AB (publ) (VICO) has an Asset Resilience Ratio of 48.38% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Vicore Pharma Holding AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Vicore Pharma Holding AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr590.06 Million | 48.38% |
| Total Liquid Assets | Skr590.06 Million | 48.38% |
Asset Resilience Insights
- Very High Liquidity: Vicore Pharma Holding AB (publ) maintains exceptional liquid asset reserves at 48.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vicore Pharma Holding AB (publ) Industry Peers by Asset Resilience Ratio
Compare Vicore Pharma Holding AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Vicore Pharma Holding AB (publ) (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Vicore Pharma Holding AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 48.38% | Skr590.06 Million | Skr1.22 Billion | -- |
| 2024-12-31 | 0.00% | Skr0.00 | Skr1.20 Billion | -- |
| 2023-12-31 | 29.94% | Skr149.04 Million | Skr497.84 Million | +28.48pp |
| 2022-12-31 | 1.46% | Skr4.94 Million | Skr338.01 Million | -15.61pp |
| 2021-12-31 | 17.07% | Skr77.00 Million | Skr451.17 Million | -0.15pp |
| 2020-12-31 | 17.22% | Skr70.00 Million | Skr406.51 Million | -5.35pp |
| 2019-12-31 | 22.57% | Skr77.00 Million | Skr341.11 Million | +22.57pp |
| 2018-12-31 | 0.01% | Skr21.00K | Skr301.60 Million | -- |